Cancer Targeted Therapy in India
India is one of the world's largest producers of generic oncology drugs. All major targeted therapy agents — EGFR inhibitors, HER2-targeted antibodies, VEGFR inhibitors, CDK4/6 inhibitors, PARP inhibitors, and BCR-ABL inhibitors — are available at a fraction of Western costs.
Check Your Eligibility — Free
Send your reports. Our specialists will review and confirm whether Targeted Therapy is right for your case.
📋 Get Free Assessment| Cost Comparison | India | USA |
|---|---|---|
| Targeted Therapy | $200–$2,000 per month | $5,000–$20,000 per month |
| Savings | 60–80% less than USA | |
Conditions Treated with Targeted Therapy
- NSCLC with EGFR mutation (Osimertinib, Gefitinib)
- HER2+ breast cancer (Trastuzumab, Pertuzumab)
- CML (Imatinib, Nilotinib, Dasatinib)
- GIST (Imatinib, Sunitinib)
- CLL (Ibrutinib, Venetoclax)
- BRCA+ cancer (Olaparib, Niraparib)
- HR+ breast cancer (Palbociclib, Ribociclib, Abemaciclib)
How Targeted Therapy Works (Step by Step)
- Comprehensive biomarker testing (NGS, IHC, FISH)
- Oncologist review of actionable mutations
- Drug selection and regimen design
- Pharmacy dispensing (oral pills or IV infusion)
- Response monitoring (imaging, biomarkers)
- Toxicity management and dose modifications
Benefits of Targeted Therapy in India
- Precision medicine — only targets cancer cells with specific mutations
- Oral pills for many agents (easier than IV chemotherapy)
- Generic biosimilars available for 80–90% of targeted agents
- Reduced side effects vs systemic chemotherapy
- NGS panels (Foundation One equivalent) available in India
Best Hospitals for Targeted Therapy in India
- Tata Memorial Hospital, Mumbai
- Apollo Cancer Centre, Chennai
- AIIMS, New Delhi
- Fortis Memorial Research Institute, Gurugram
- Rajiv Gandhi Cancer Institute, Delhi
Frequently Asked Questions
Q: Can I access targeted therapy drugs in India that are approved in the USA?
A: Yes. All FDA-approved targeted therapy drugs are available in India — either as the branded version or as a generic/biosimilar at 70–85% lower cost. Osimertinib (Tagrisso) costs $400/month in India vs $18,000/month in the USA.